Plasma cannabinoid pharmacokinetics following the inhalation of vaporised cannabis with and without cannabidiol.
Plasma cannabinoid pharmacokinetics following the inhalation of vaporised cannabis with and without cannabidiol.
CBD co-administration does not significantly alter THC plasma concentrations when cannabis is vaporized and inhaled in controlled conditions.
This controlled study provides evidence that CBD does not meaningfully interfere with THC absorption or metabolism when cannabis is vaporized. The crossover design with weight-adjusted dosing offers more precision than previous observational studies that showed mixed results.
Patients and clinicians often assume CBD will reduce THC effects through pharmacokinetic interference, but this data suggests the interaction may be primarily pharmacodynamic. This informs dosing decisions when patients use THC:CBD combination products.
| Study Type | Randomized Controlled Trial |
| Population | 48 participants aged 16-17 years and 26-29 years |
| Intervention | Vaporized THC-alone (8mg THC/75kg) vs THC+CBD (8mg THC + 24mg CBD/75kg) |
| Comparator | Placebo control |
| Primary Outcome | Plasma THC and metabolite concentrations |
| Key Finding | CBD presence did not significantly alter THC pharmacokinetics |
| Journal | Drug and Alcohol Dependence |
| Year | 2024 |
When counseling patients using vaporized cannabis products containing both THC and CBD, clinicians should not expect CBD to significantly reduce THC blood levels. Any modulating effects of CBD on THC are likely occurring at the receptor level rather than through altered absorption or metabolism.
The abstract does not provide the actual plasma concentration values, statistical significance data, or details about the metabolite profiles. It also does not address whether age differences in pharmacokinetics were observed, despite this being a stated study aim.
The study used specific weight-adjusted doses that may not reflect real-world usage patterns. Vaporization represents only one delivery method, and results may not apply to other consumption routes like edibles or smoking.
This well-controlled study challenges assumptions about CBD reducing THC bioavailability through pharmacokinetic mechanisms. However, the clinical implications remain limited without seeing the actual concentration data and effect sizes from the full publication.
Join the Conversation
Have a question about how this applies to your situation? Ask Dr. Caplan →
Want to discuss this topic with other patients and caregivers? Join the forum discussion →
Have thoughts on this? Share it:
FAQ
Does CBD affect how THC is absorbed and processed in the body when vaping cannabis?
Based on this controlled study, CBD co-administration does not significantly alter THC plasma concentrations when cannabis is vaporized and inhaled. This finding suggests that CBD does not meaningfully interfere with THC absorption or metabolism through inhalation routes.
Are there differences in cannabis pharmacokinetics between adolescents and adults?
This study specifically examined cannabinoid plasma pharmacokinetics in both adolescents (16-17 years) and adults (26-29 years) to understand age-related differences. The research provides important data on how age may moderate cannabis processing, though specific results would require reviewing the complete study findings.
What dosages were used in this study and how do they relate to clinical practice?
The study used weight-adjusted dosing of 8mg THC alone or combined with 24mg CBD per 75kg body weight via vaporization. These controlled dosages provide clinically relevant pharmacokinetic data for medical cannabis prescribing and patient counseling regarding vaporized cannabis products.
How quickly does vaporized cannabis reach peak blood levels?
Blood samples were collected at 20, 30, and 160 minutes post-inhalation to track cannabinoid absorption patterns. This timeframe captures the rapid onset characteristic of inhaled cannabis, providing clinicians with evidence-based timing for peak plasma concentrations and duration of measurable levels.
Why is this pharmacokinetic research clinically important for cannabis medicine?
Understanding how CBD affects THC pharmacokinetics is crucial for optimizing medical cannabis formulations and predicting drug interactions. This randomized, double-blind, placebo-controlled study provides high-quality evidence to guide clinical decision-making regarding cannabis product selection and dosing strategies.
